Vivo Bio Tech Limited has scheduled its 39th Annual General Meeting (AGM) for September 30, 2026. The meeting will be conducted via Video Conferencing or Other Audio Visual Means (VC/OVAM).

The board of directors approved this schedule during a meeting held on August 22, 2026. The session commenced at 7:16 pm and concluded at 7:31 pm.

Board Approvals and Director Re-Appointments

The board also approved the re-appointment of three whole-time directors. These appointments are subject to shareholder approval at the upcoming AGM.

Mr Kalyan Ram Mangipudi retires by rotation and has offered himself for re-appointment. He brings over 23 years of experience in accounting, finance, and administration.

Based on recommendations from the Nomination and Remuneration Committee, the board approved two additional five-year terms:

• Mr Sri Kalyan Kompella: Appointed from November 3, 2026, to November 2, 2031. He has over 25 years of experience in accounting, finance, and administration.
• Dr Sankaranarayanan Alangudi: Appointed from January 6, 2027, to January 5, 2032. He is a discovery biologist with more than 45 years of experience in pharmaceutical R&D.

Corporate Governance Disclosures

The board approved the Board Report, Corporate Governance Report, and Management Discussion and Analysis report for the financial year ended March 31, 2026. These documents include all necessary annexures as required by regulatory standards.

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company cited SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/20266 dated January 30, 2026, in its filing.

No relationships between the directors were disclosed in the filing.

Vivo Bio Tech Limited returned to profitability in the first quarter of FY26, reporting a consolidated net profit of ₹18.76 lakh for the period ended June 30, 2026. This marks a significant recovery from the net loss of ₹516.27 lakh recorded in the quarter ended March 31, 2026. Revenue from operations for the quarter stood at ₹1,427.97 lakh, a slight increase from the ₹1,420.11 lakh reported in the previous quarter.

The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on July 13, 2026. The results have been reviewed by the Audit Committee and are subject to a limited review by the Statutory Auditors, M/s. P. Murali & Co., Chartered Accountants. The financial statements were prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

On a standalone basis, the company reported a net profit of ₹18.43 lakh for Q1FY26, reversing the net loss of ₹543.69 lakh in Q4FY26. Standalone revenue from operations rose to ₹1,413.94 lakh from ₹1,376.72 lakh in the preceding quarter. Total income for the quarter was ₹1,419.48 lakh, while total expenses were reported at ₹1,385.95 lakh.

The consolidated results include the performance of the company's subsidiaries: Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited, and Vivobio Consulting Services Private Limited. The company operates in a single segment, Bio Technology, and therefore segmental reporting is not required.

Earnings per equity share (basic and diluted) for the consolidated results were reported at ₹0.08 for Q1FY26, an improvement from the negative ₹2.52 per share recorded in the previous quarter. The paid-up share capital of the company remained at ₹2,219.06 lakh during the period.